We report the case of a woman with intracranial metastasis from an esophageal gastrointestinal stromal tumor (GIST) with the mutation site in the 3' end of exon 11. Frontal craniotomy was performed with complete resection of the mass, followed by postoperative stereotaxic radiotherapy (SRT). Intracranial metastasis from GISTs is extremely rare; we found only seven case reports in the literature.
Introduction

Gastrointestinal stromal tumors (GISTs) account for at least 80% of all mesenchymal tumors of the gastrointestinal tract, where they arise from precursors of the interstitial cells of Cajal (1). Clinically, GISTs are usually diagnosed on the basis of KIT (CD117) expression on immunohistochemical analysis (2). About 70% of the GISTs are located in the stomach, 20% in the small bowel, and 5% in the rectum (3). Smaller portions of GISTs occur in the esophagus or outside the gastrointestinal tract. Recurrent disease arises mainly in the original site or via hematogenous metastasis or peritoneal dissemination. Intracranial metastasis is extremely rare, and our review of the literature revealed only seven reports
.
The gain of function of the c-kit or platelet-derived growth factor receptor alpha (PDGFRA) genes plays a critical oncogenic role in GISTs (2, 11 (Fig. 3) .
F i g u r e 2 . B r a i n CT i ma g e . Ax i a l b r a i n CT i ma g e s h o wi n g a 5 c m h e t e r o g e n e o u s l e s i o n i n t h e l e f t f r o n t a l l o b e wi t h s i g n i f i c a n t p e r i f o c a l e d e ma a n d mi d l i n e s h i f t .
F i g u r e 3 . F DG-P E T i ma g e . F DG-P E T s h o wi n g n o F DG u pt a k e i n c l u d i n g i n t h e l i v e r .
F i g u r e 4 . I mmu n o h i s t o c h e mi c a l s t a i n o f c e r e b r a l me t a s t a s i s . I mmu n o h i s t o c h e mi c a l s t a i n f o r CD1 1 7 ( c -k i t ) s h o wi n g s t a i ni n g o f t h e c e l l me mb r a n e ( × 4 0 0 ) .
Frontal craniotomy was performed with complete resection of the mass, followed by postoperative stereotaxic radiotherapy (SRT (Fig. 4) . Mutation analysis showed that six amino-acid residues corresponding to glutamine (Gln) followed by five amino acids codons 575-579 were inserted between codon 579 and codon 580 in exon 11 (Fig. 5) . This finding was consistent with the mutation site of the patient's 
F i g u r e 5 . DNA s e q u e n c e o f e x o n 1 1 o f c -k i t . DNA s e q u e n c e o f e x o n 1 1 o f c -k i t o f c o n t r o l ( u p p e r ) a n d p a t i e n t ( l o we r ) . Mu t a t i o n a l a n a l y s i s r e v e a l e d a t a n d e m d u p l i c a t i o n b e t we e n c o d o n 5 7 9 a n d 5 8 0 . S i x a mi n o -a c i d r e s i d u e s c o r r e s p o n d i n g t o g l u t a mi n e ( Gl n ) f o l l o we d b y f i v e a mi n o a c i d s c o d o n s 5 7 5 -5 7 9 we r e i n s e r t e d b e t we e n c o d o n
T a b l e . S e v e n Ca s e Re p o r t o f GI S T wi t h I n t r a c r a n i a l Me t a s t a s i s
esophageal GIST. Subsequently, the patient remained well and no recurrence was found during six months of follow up after her craniotomy.
Discussion
We report the case of a woman with intracranial metastasis from an esophageal GIST with the mutation site in the 3' end of exon 11, and systemic disease progression appeared to be controlled for two years after stopping imatinib mesylate prescribed for liver metastasis. The original tumor diameter was more than 10 cm, putting the patient in a high risk category for recurrent or metastatic disease according to NIH criteria (19) (Table) (4) (5) (6) (7) (8) (9) (10) . Of these, four were treated surgically (4, (7) (8) (9) and one of these case received radiotherapy as an additional treatment (7) . Another case was treated with radiotherapy alone to relieve pain (10) . Only one case of the three cases treated with imatinib mesylate responded to treatment (5 
